期刊文献+

经尿道膀胱肿瘤绿激光汽化术联合髂内动脉介入栓塞化疗治疗高龄高危浸润性膀胱癌临床观察 被引量:5

Clinical observation of RPVBT combined with internal iliac artery chemoembolization in the treatment of muscle-invasive bladder cancer of elderly and high-risk patients
下载PDF
导出
摘要 目的探讨应用根治性经尿道膀胱肿瘤绿激光汽化术(radical transurethral photoselective vaporization of bladder tumours,RPVBT)联合髂内动脉介入栓塞灌注化疗治疗肌层浸润性膀胱癌(T2N0M0)高龄、高危患者的临床疗效及安全性。方法选取因无法耐受或不愿接受根治性膀胱全切手术,而接受RPVBT或根治性经尿道膀胱肿瘤等离子切除术(radical of transurethral resection of bladder tumours,RTURBT),联合髂内动脉介入栓塞化疗的108例肌层浸润性膀胱癌(T2N0M0)患者资料。根据已实施术式不同,分为RTURBT组47例,RPVBT组61例,分析比较2组手术时间、术中出血量、闭孔反射情况、住院时间、生存率,复发率、以及总体髂内动脉介入栓塞化疗不良反应情况,绘制总体生存及无进展生存曲线。结果RPVBT组与RTURBT组患者年龄、Karnofsky评分、肿瘤最大直径、肿瘤数量、肿瘤分布位置、病理级别构成、性别构成等观测变量比较差异均无统计学意义(P>0.05)。RPVBT组患者术中出血量、手术时间、术后血尿时间、住院时间各观测变量显著优于RTURBT组患者,且未出现闭孔神经反射,差异均有统计学意义(P<0.001)。5年累积生存率、无进展生存率、累积复发率情况,RPVBT组分别为68.0%、43.3%、38.9%,RTURBT组分别为69.8%、47.8%、45.2%,2组比较差异无统计学意义(P>0.05)。2组复发特点以非浸润性复发为主(46.8%、42.6%),肌层浸润性复发率低(4.3%、4.9%)。总体髂内动脉介入栓塞化疗相关不良反应低、耐受性好。结论RPVBT联合髂内动脉介入栓塞化疗方案治疗肌层浸润性膀胱癌更微创、更小的不良反应、易耐受性、安全有效,有较满意的远期总体生存率,可作为高龄、高危无法耐受或不愿意接受根治手术患者的治疗策略。 Objective To investigate the clinical efficacy and safety of radical transurethral photoselective vaporization of bladder tumors(RPVBT)combined with internal iliac artery chemoembolization in the treatment of muscle-invasive bladder cancer(T2N0M0)in elderly and high-risk patients.Methods The clinical data were collected from 108 patients with muscle-invasive bladder cancer(T2N0M0),who chose to undergo RPVBT or radical transurethral resection ofbladder tumors(RTURBT)combined with internal iliac artery chemoembolization due to intolerance or reluctance to undergo radical cystectomy(RC).According to different types of surgical methods performed,they were divided into the RTURBT group(n=47)and the RPVBT group(n=61).The duration of operation,intraoperative blood loss,obturator nerve reflex,length of hospital stay,survival rate,recurrence rate and overall incidence of adverse effects after internal iliac artery chemoembolization were analyzed and compared between the two groups.Overall survival(OS)and progression-free survival(PFS)curves were drawn.Results There were no statistically significant differences between the RPVBT group and the RTURBT group in terms of age,Karnofsky score,maximum tumor diameter,tumor number,location for tumor distribution,pathological grade composition,and gender composition(P>0.05).In the RPVBT group,the observed variables of intraoperative blood loss,duration of operation,postoperative hematuria days,and length of hospital stay were significantly less or shorter than those in the RTURBT group,and no obturator nerve reflex occurred,suggesting significant differences(P<0.001).The 5-year cumulative survival rate,PFS rate,and cumulative recurrence rate were 68.0%,43.3%,and 38.9%in the RPVBT group,and 69.8%,47.8%,and 45.2%in the RTURBT group,respectively,and there was no statistically significant difference between two groups(P>0.05).The recurrence characteristics of the two groups were mainly non-invasive recurrence(46.8%vs.42.6%),and the recurrence rate of muscular invasive bladder cancer was lower(4.3%vs.4.9%).The adverse reactions overall related to internal iliac artery chemoembolization were low,with good tolerance.Conclusion RPVBT combined with internal iliac artery chemoembolization is more minimally invasive,which has low complications,good tolerance,good safety and effectiveness in the treatment of muscle-invasive bladder cancer.With a satisfactory long-term OS rate,RPVBT can be used as a treatment strategy for high-risk elderly patients who are intolerant or unwilling to undergo radical surgery.
作者 任行飞 冯金顺 李世祥 费兴业 张同庆 葛永超 REN Xing-fei;FENG Jin-shun;LI Shi-xiang;FEI Xing-ye;ZHANG Tong-qing;Ge Yong-chao(Department of Urology, the Third People′s Hospital of Zhengzhou, Cancer Hospital of Henan University, Henan Province, Zhengzhou 450000, China;Department of Interventional Radiology, the Third People′s Hospital of Zhengzhou, Cancer Hospital of Henan University, Zhengzhou 450000, China)
出处 《河北医科大学学报》 CAS 2021年第6期680-685,共6页 Journal of Hebei Medical University
基金 河南省科技厅科技攻关计划项目(172102310684)。
关键词 膀胱肿瘤 激光疗法 抗肿瘤联合化疗方案 urinary bladder neoplasms laser therapy antineoplastic combined chemotherapy protocols
  • 相关文献

参考文献7

二级参考文献63

  • 1黄健.膀胱癌诊断治疗指南[M]//那彦群,叶章群,孙颖浩等.中国泌尿外科疾病诊断治疗指南(2014版),北京:人民卫生出版社,2014:36-37.
  • 2Khosravi-SHahi P,Cabez6n-Guti6rrez L. Selective organpreservation in muscle-invasive bladder cancer: review of theliterature[ J]. Surg Oncol,2012,21:17-22.
  • 3Abe T, Yoshioka T, Sato M, et al. Bladder preservation usingchemoradiation therapy for locally invasive bladder cancer [ J ].Nihon Hinyokika Gakkai Zasshi,2011,102 : 14-22.
  • 4Ikeda M,Matsumoto K,Nishi M, et al. Comparison of radicalcystectomy and chemoradiotherapy in patients with locallyadvanced bladder cancer[ J]. Asian Pac J Cancer Prev,2014,15 :6519-6524.
  • 5Han B,Liang S,Jing Y, et ai. Organ preservation for muscle-invasive bladder cancer by preoperative intra-arterial chemotherapyand transurethral resection[ J]. Med Oncol,2014,31 :912.
  • 6Maarouf AM, Khalil S, Salem EA, et al. Bladder preservationmultimodality therapy as an alternative to radical cystectomy fortreatment of muscle invasive bladder cancer[ J]. BJU Int, 2011 ,107:1605-1610.
  • 7Krause FS, Walter B, Ott OJ, et al. 15-year survival rates aftertransurethral resection and radiochemotherapy or radiation inbladder cancer treatment[ J]. Anticancer Res,2011,31:985-90.
  • 8Efstathiou JA,Spiegel DY, Shipley WXJ,et al. Long-term outcomesof selective bladder preservation by combined-modality therapy forinvasive bladder cancer: the MGH experience [ J ]. Eur Urol,2012,61:705-711.
  • 9G6mez Sancha F, Bachmann A, Choi BB, et al. Photoselectivevaporization of the prostate ( GreenLight PV) : lessons learnt after3500 procedures[ J] . Prostate Cancer Prostatic Dis,2007 ,10 :316-322.
  • 10Tao W,Yang D,Shan Y,et al. Safety and efficacy of 120W highperformance system greenlight laser vaporization for non-muscle-invasive bladder cancer [ J]. J Xray Sci Technol,2013 ,21 : 309-316.

共引文献78

同被引文献54

引证文献5

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部